Annexon holds virtual R&D Day focusing on Guillain-Barré Syndrome program

Annexon, Inc.

Presentation highlighted serious unmet need in Guillain-Barré Syndrome and Annexon's novel therapeutic approach.
Webcast archive available on investor page for 30 days; CEO Douglas Love presented.
No financial results, guidance, or clinical data disclosed in the filing.

item 7.01 item 9.01

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-058031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.